Sign In
Buy BBIO
$80.09
-2.05 (-2.50%)
At Close: Jul 31, 2026
Buy the Dip on This Biotech Stock After Recent Fall
02:44pm, Monday, 09'th Feb 2026
BridgeBio Pharma Inc (NASDAQ:BBIO) stock pulled back sharply from its Jan. 22 record high of $81.33, marking a three-month low after Pfizer withdrew a tafamidis patent in the European Union (EU).
BridgeBio Pharma (BBIO) Surges 6.8%: Is This an Indication of Further Gains?
04:30am, Monday, 09'th Feb 2026
BridgeBio Pharma (BBIO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term
BridgeBio: Initiating At A Neutral Rating, Stock Priced At Perfection
01:10am, Monday, 09'th Feb 2026
I initiate BridgeBio with a Neutral rating and a $74 target price, reflecting balanced opportunity and risk. ATTR-CM launch of Attruby reduces binary risk, but commercial sustainability and pricing du
BridgeBio Pharma (NASDAQ:BBIO) Shares Gap Up – Still a Buy?
02:58am, Sunday, 08'th Feb 2026
BridgeBio Pharma, Inc. (NASDAQ: BBIO - Get Free Report) gapped up prior to trading on Friday. The stock had previously closed at $63.73, but opened at $70.07. BridgeBio Pharma shares last traded at $6
CORRECTING and REPLACING -- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
05:10pm, Tuesday, 27'th Jan 2026
PALO ALTO, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by BridgeBio Pharma, Inc. (Nasdaq: BBIO), please note that some of the figures in the fir
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Tuesday, 27'th Jan 2026
PALO ALTO, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases,
BridgeBio Pharma, Inc. $BBIO Shares Sold by Harvey Capital Management Inc.
04:55am, Monday, 26'th Jan 2026
Harvey Capital Management Inc. lessened its holdings in BridgeBio Pharma, Inc. (NASDAQ: BBIO) by 16.8% during the undefined quarter, according to its most recent disclosure with the Securities and Exc
BridgeBio Pharma, Inc. $BBIO Shares Sold by Emerald Advisers LLC
04:49am, Thursday, 22'nd Jan 2026
Emerald Advisers LLC lessened its stake in BridgeBio Pharma, Inc. (NASDAQ: BBIO) by 29.5% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange
PALO ALTO, Calif., Jan. 15, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (the “Company,” “we” or “BridgeBio”), a new type of biopharmaceutical company focused on genetic
-- The transaction is intended to strengthen the balance sheet, lower interest expense, reduce dilution, and significantly extend debt maturity
BridgeBio Pharma, Inc. (BBIO) Presents at 44th Annual J.P. Morgan Healthcare Conference Prepared Remarks Transcript
02:25pm, Monday, 12'th Jan 2026
BridgeBio Pharma, Inc. (BBIO) Presents at 44th Annual J.P. Morgan Healthcare Conference Prepared Remarks Transcript
- Preliminary unaudited Q4 and Full Year 2025 net Attruby ® product revenue of $146.0 million and $362.4 million, respectively
BridgeBio Pharma, Inc. (BBIO) Discusses Achondroplasia Pathophysiology, Unmet Needs, and PROPEL 3 Infigratinib Phase 3 Study Transcript
BridgeBio to Participate in the J.P. Morgan Healthcare Conference
07:30am, Monday, 05'th Jan 2026
PALO ALTO, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases,
BridgeBio to Host Achondroplasia Investor Webinar on Friday, January 9th at 8:00 am ET
07:30am, Friday, 02'nd Jan 2026
PALO ALTO, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases,
